Cox regression analysis of impact of frailty status on OS, PFS, and cumulative incidence of TRM for patients who received chemotherapy in the total cohort
| Frailty score . | Frailty group . | Total cohort, patients receiving chemotherapy . | Total cohort, patients receiving R-CHOP . | ||||
|---|---|---|---|---|---|---|---|
| 2-y OS . | 2-y PFS . | 2-y cumulative incidence TRM . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | Subdistribution HR (95% CI) . | P . | ||
| Unadjusted | |||||||
| 1.0 | Fit | 1 | 1 | 1 | |||
| 1.5-3.0 | Unfit | 3.65 (2.53-5.26) | <.001 | 3.39 (2.42-4.75) | <.001 | 2.90 (1.39-6.03) | .004 |
| >3.0 | Frail | 9.05 (6.24-13.1) | <.001 | 7.93 (5.62-11.2) | <.001 | 5.75 (2.57-12.8) | <.001 |
| Frail vs unfit | 2.48 (1.91-3.22) | <.001 | 2.34 (1.81-3.02) | <.001 | 1.99 (1.04-3.77) | .036 | |
| Adjusted* | |||||||
| 1.0 | Fit | 1 | 1 | 1 | |||
| 1.5-3.0 | Unfit | 2.41 (1.63-3.56) | <.001 | 2.31 (1.60-3.32) | <.001 | 3.57 (1.48-8.61) | .005 |
| >3.0 | Frail | 4.15 (2.63-6.54) | <.001 | 3.76 (2.43-5.81) | <.001 | 8.52 (2.35-30.9) | .001 |
| Frail vs unfit | 1.72 (1.27-2.34) | .001 | 1.63 (1.21-2.20) | .001 | 2.39 (1.05-5.44) | .038 | |
| Frailty score . | Frailty group . | Total cohort, patients receiving chemotherapy . | Total cohort, patients receiving R-CHOP . | ||||
|---|---|---|---|---|---|---|---|
| 2-y OS . | 2-y PFS . | 2-y cumulative incidence TRM . | |||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | Subdistribution HR (95% CI) . | P . | ||
| Unadjusted | |||||||
| 1.0 | Fit | 1 | 1 | 1 | |||
| 1.5-3.0 | Unfit | 3.65 (2.53-5.26) | <.001 | 3.39 (2.42-4.75) | <.001 | 2.90 (1.39-6.03) | .004 |
| >3.0 | Frail | 9.05 (6.24-13.1) | <.001 | 7.93 (5.62-11.2) | <.001 | 5.75 (2.57-12.8) | <.001 |
| Frail vs unfit | 2.48 (1.91-3.22) | <.001 | 2.34 (1.81-3.02) | <.001 | 1.99 (1.04-3.77) | .036 | |
| Adjusted* | |||||||
| 1.0 | Fit | 1 | 1 | 1 | |||
| 1.5-3.0 | Unfit | 2.41 (1.63-3.56) | <.001 | 2.31 (1.60-3.32) | <.001 | 3.57 (1.48-8.61) | .005 |
| >3.0 | Frail | 4.15 (2.63-6.54) | <.001 | 3.76 (2.43-5.81) | <.001 | 8.52 (2.35-30.9) | .001 |
| Frail vs unfit | 1.72 (1.27-2.34) | .001 | 1.63 (1.21-2.20) | .001 | 2.39 (1.05-5.44) | .038 | |
The table show both unadjusted results, and results adjusted for IPI score, Ann Arbor stage, age group, and ECOG PS. The P value is shown in bold when below a 5% significance threshold. Univariate and multivariate Cox regression analysis was performed with HR for 2-year OS, 2-year PFS, and 2-year cumulative incidence of TRM.
All patients in the total cohort who could be classified into a frailty group and had received chemotherapy were included in the analyses for 2-year OS and 2-year PFS (n = 604). Patients who did not receive chemotherapy were excluded from the analyses. This was done to evaluate the prognostic and discriminative power of the frailty grouping in patients who were candidates for chemotherapy, as well as to avoid exaggerated HR for the frail group due to this poor prognostic group. Analyses for TRM were performed for patients who received R-CHOP (n = 469). Missing values were imputed using MICE. Follow-up was limited to 2 years to obtain proportional hazard for the frail group. Harrell’s C Index for 2-year OS was 0.71 for the unadjusted model and 0.77 for the adjusted model.
Adjusted for all IPI groups (IPI 1, 2, 3, and 4-5), all stages (I, II, III, and IV), 4 age groups (70-74, 75-79, 80-84, and ≥85 years), and ECOG PS (0, 1, 2, 3, and 4).